Scarica l'app Stockscreener
53.24
4.00%
-2.22
Dopo l'orario di chiusura:
53.20
-0.04
-0.08%
Precedente Chiudi:
$55.46
Aprire:
$55.572
Volume 24 ore:
3.82M
Relative Volume:
1.90
Capitalizzazione di mercato:
$10.29B
Reddito:
$3.24B
Utile/perdita netta:
$348.90M
Rapporto P/E:
29.88
EPS:
1.7817
Flusso di cassa netto:
$717.02M
1 W Prestazione:
-0.11%
1M Prestazione:
-4.07%
6M Prestazione:
+0.83%
1 anno Prestazione:
-14.21%
Intervallo 1D:
$52.65
$57.44
Intervallo di 1 settimana:
$52.45
$57.44
Portata 52W:
$50.76
$66.28
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
53.24 | 10.72B | 3.24B | 348.90M | 717.02M | 1.7817 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Ripresa | Morgan Stanley | Overweight |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-20 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Downgrade | Stifel | Buy → Hold |
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised - sharewise.com
BioMarin (NASDAQ: BMRN) Q1 profit drops as $4.8B Amicus acquisition ramps - Stock Titan
BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush Says - marketscreener.com
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says - marketscreener.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2026 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical Q1 2026: $0.76 EPS Falls Short — Deep Dive - AlphaStreet
Bernstein SocGen lowers BioMarin stock price target on guidance update By Investing.com - Investing.com Canada
MSN Money - MSN
Evercore ISI raises BioMarin stock price target on valuation gap - Investing.com
BMRN Q1 Deep Dive: Amicus Acquisition, Pipeline Milestones, and Order Dynamics Shape Outlook - TradingView
BioMarin Boosts 2026 Outlook After Amicus Deal - TipRanks
BioMarin Q1 2026 Earnings Preview: Revenue Growth Expected to SlowNews and Statistics - IndexBox
BioMarin Pharmaceutical Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
BioMarin (BMRN) Q1 2026 Earnings Transcript - AOL.com
BMRN: Amicus acquisition drives 20% 2026 revenue growth outlook and portfolio expansion - TradingView
BioMarin Q1 2026 slides: revenue beats forecast, eyes 20% growth - Investing.com
BioMarin Pharmaceutical Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: BioMarin Q1 2026 beats EPS forecasts, stock dips slightly - Investing.com
Transcript: Biomarin Pharmaceutical Q1 2026 Earnings Conference Call - Benzinga
BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates - Yahoo Finance
BioMarin Pharmaceutical Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BMRN) 2026-05-04 - Seeking Alpha
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q1 Earnings Miss Masked by Raised 2026 Guidance - ChartMill
BioMarin Pharmaceutical Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Guidance Revised - marketscreener.com
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Reports Q1 Revenue $766.2M, vs. FactSet Est of $752.2M - marketscreener.com
BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com Nigeria
(BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Revenue Range $3.83B$3.93B - marketscreener.com
BioMarin beats estimates, raises guidance on Amicus deal - Investing.com
BioMarin: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q1 Adjusted EPS $0.76 per Share, vs. FactSet Est of $0.91 - marketscreener.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Misses Q1 CY2026 Revenue Estimates - Yahoo Finance
BioMarin (NASDAQ: BMRN) raises 2026 sales view following Amicus deal - Stock Titan
BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioMarin Reports First Quarter 2026 Financial and Operating Results - PR Newswire
Mucopolysaccharidoses Market to Reach USD 4,389.85 Million - openPR.com
BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
BioMarin Pharmaceutical Q1 2026 earnings preview - MSN
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting - The AI Journal
Biomarin presents new data on the effect of long-term treatment with Voxzogo® (vosoritide) on arm span, bone health and growth in children with achondroplasia - marketscreener.com
Six-year study finds bone health maintained in children on VOXZOGO - Stock Titan
Assessing BioMarin (BMRN) Valuation As Shares Show Recent Weakness And DCF Signals Deep Discount - Sahm
BioMarin acquires Amicus Therapeutics for $4.8bn - MSN
BioMarin Pharmaceutical Inc expected to post earnings of 79 cents a shareEarnings Preview - TradingView
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset - Sahm
How Will BioMarin Pharmaceutical Stock React To Its Upcoming Earnings? - Trefis
BIOMARIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc.BM - TMX Newsfile
Short Interest in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Rises By 14.9% - MarketBeat
BMRN News | BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) - ChartMill
Precision Trading with Biomarin Pharmaceutical Inc. (BMRN) Risk Zones - Stock Traders Daily
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust - Sahm
BioMarin Pharmaceutical Earnings Notes - Trefis
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):